Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

5.880 +0.380 (+6.91%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jaguar Health, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
19 20 Next >
Looking Into Jaguar Health's Return On Capital Employed
Via Benzinga
Jaguar Health Provides Updates on Presentation at the World Congress of Gastroenterology About Crofelemer for Pediatric Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDD) by Third-Party Investigator
Via ACCESSWIRE
Jaguar Health Subsidiary Napo Pharmaceuticals Sponsors Episode of The Gayly Dose Focused on HIV-related Diarrhea
Via ACCESSWIRE
Jaguar Health Hosts Symposium on the Management of Cancer Therapy-related Diarrhea
Via ACCESSWIRE
Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials
Via ACCESSWIRE
Jaguar Health to Host Investor Webcast Monday, November 14th at 8:30 AM Eastern Time Regarding Q3 2022 Financials & Corporate Updates
Via ACCESSWIRE
Jaguar Animal Health Sponsors October 26th Episode of dvm360 Live! to Drive Awareness of Canalevia-CA1 and Participation in Jaguar’s Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) Initiative
Via ACCESSWIRE
Jaguar Health Reports Voting Results from 2022 Special Meeting of Stockholders
Via ACCESSWIRE
Jaguar Health Provides Company Updates and Reports 2022 Second Quarter Financials
Via ACCESSWIRE
Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Via ACCESSWIRE
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case. 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 120 companies set new 52-week lows. 
Via Benzinga
Why Bank of America Shares Are Trading Higher? Here Are 66 Stocks Moving In Monday's Mid-Day Session
Gainers FedNat Holding Company (NASDAQ: FNHC) shares rose 78.9% to $0.93 after jumping 48% on Friday. 
Via Benzinga
Why Jaguar Health Stock Is Popping Off
Jaguar Health Inc (NASDAQ: JAGX) shares are trading higher by 12.9% to $0.16 during Monday's session after the company was granted orphan drug designation by the European Medicines agency for... 
Via Benzinga
European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Acorda Therapeutics (NASDAQ:ACOR) shares increased by 46.1% to $0.49 during Monday's pre-market session. The company's market cap stands at $11.9 million. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Good morning, investor! It's time to start off the trading week with a breakdown of the biggest pre-market stock movers on Monday! 
Via InvestorPlace
Why Acorda Therapeutics Shares Are Trading Higher By 55%; Here Are 28 Stocks Moving Premarket
Gainers 
Via Benzinga
Jaguar Animal Health Co-Sponsoring Closing Ceremony at Veterinary Cancer Society Annual Conference on October 15th to Drive Awareness of Jaguar's Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) Initiative
Via ACCESSWIRE
Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of Investigational New Drug (IND) Application for NP-300, a Novel Drug Candidate for the Symptomatic Relief and Treatment of Diarrhea from Cholera and Other Pathogens
Via ACCESSWIRE
Jaguar Health to Present at Lytham Partners Fall 2022 Investor Conference on September 28th and at Ladenburg Thalmann 2022 Healthcare Conference on September 29th
Via ACCESSWIRE
Why NeuroBo Pharmaceuticals Is Trading Higher By Around 55%; Here Are 25 Stocks Moving Premarket
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) rose 54.6% to $26.07 in pre-market trading after the company entered into an exclusive license agreement with Dong-A. 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Jaguar Health Seeks FDA Nod For Cholera Candidate Study
Jaguar Health (NASDAQ: JAGX) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for its subsidiary Napo's NP-300 drug product candidate for the... 
Via Benzinga
Jaguar Health Announces Submission of Investigational New Drug (IND) Application to FDA for Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
Via ACCESSWIRE
Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream
Via ACCESSWIRE
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Looking Into Jaguar Health's Return On Capital Employed
According to Benzinga Pro data, during Q2, Jaguar Health (NASDAQ:JAGX) posted sales of $2.92 million. Earnings were up 48.3%, but Jaguar Health still reported an overall loss of $9.39 million. 
Via Benzinga
Jaguar Health Announces that Orphan Drug Designation Application Submitted to the FDA for Crofelemer for a Severe Congenital Diarrheal Disorder (CDD) Has Been Accepted for Review
Via ACCESSWIRE
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.8% to $0.97 during Monday's after-market session. The company's market cap stands at $31.6 million. 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.